Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Ethylretinamide is a synthetic derivative of all-trans-retinoic acid (vitamin A acid), specifically the ethylamide of all-trans β-retinoic acid. It has a molecular formula of C22H33NO and a molecular weight of approximately 327.5 g/mol. The compound is structurally related to retinoids, which are known for their roles in cell differentiation, proliferation, and apoptosis through modulation of nuclear retinoic acid receptors (RARs). While detailed pharmacological data or clinical use information for N-Ethylretinamide itself is limited in the available sources, its structure suggests it may act as a modulator of retinoid signaling pathways[8][10]. No approved therapeutic indications or marketed products containing this compound were identified.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-ethylretinamide.